CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)drug
Likely dose
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) 850 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00447330
NCT00447330Phase 2Completed
CompareCT.gov

A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

Duke University·interventional·Posted Mar 14, 2007·Updated Feb 13, 2015

In Brief

A Phase 2 clinical trial evaluating capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) for Esophageal Neoplasms and 2 related conditions. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
CountriesUnited States
CollaboratorsHoffmann-La Roche, Sanofi, Genentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 14, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 19.3 years ago

Interventions

capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)drug

Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle. Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle. Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin.